How safe is your Stem Cell Therapy for my Traumatic Brain Injury?
Stem cell therapy using mesenchymal stromal cells (MSCs) has a generally favorable safety profile in clinical research, including in people with neurological conditions, but "safe" depends on the details: the type of cells, the route of administration, the dose, the patient's current health and how carefully the treatment is screened and monitored.

For traumatic brain injury (TBI), Stem Cell Mexico uses allogeneic MSCs derived from umbilical cord tissue, usually given by intravenous (IV) infusion, which avoids brain surgery. The most common side effects of IV MSC infusions are temporary fever, headache and fatigue. Serious complications are rare in published trials, but they are possible with any medical procedure, and some people with TBI have additional risks, such as seizures, a shunt or blood thinners, that require careful evaluation. Not every person with a brain injury is a candidate, and our specialists decline treatment when the expected risks outweigh the potential benefit.
This guide explains what is known about safety, which factors increase or reduce risk, and how a responsible evaluation protects you.
What safety means in cell therapy
When doctors talk about safety, they consider several questions:
- Is the cell product safe? Are the cells properly sourced, tested for sterility and infectious agents, and documented?
- Is the procedure safe? Are the route, dose and technique appropriate, and is there monitoring?
- Is the patient a safe candidate? Are there conditions that increase the risk of complications?
- Are there long-term risks? What does follow-up show over months and years?
A truly safe treatment addresses all four.
What the evidence says about MSC safety
Large analyses of intravenous MSCs
- A systematic review and meta-analysis in EClinicalMedicine (Thompson and colleagues, 2020) analyzed 55 randomized controlled trials with 2,696 patients receiving intravascular MSCs. MSCs were associated with an increased risk of fever, but not with acute infusion toxicity, infection, thrombotic events, malignancy or death, and no trials were stopped for safety reasons.
- A 2026 updated analysis focused specifically on umbilical cord MSCs, published in Stem Cells Translational Medicine (Hum and colleagues), included 42 randomized trials with 2,280 patients. It again found a higher risk of temporary fever, with no signals of harm for infection, thrombosis, malignancy, ectopic tissue formation or death, while recommending continued long-term surveillance.
TBI-specific research
The largest randomized TBI cell therapy trial, STEMTRA, published in Neurology, tested a modified bone-marrow-derived MSC product implanted surgically around the injured brain tissue in people with chronic TBI. The treatment was generally well tolerated, and adverse events were largely related to the neurosurgical procedure, such as headache. This trial shows that cell therapy can be studied safely in chronic TBI under controlled conditions, but its surgical route carries different risks than an IV infusion.
What this means
For IV umbilical cord MSCs, the best available evidence suggests a low rate of serious complications in controlled settings. Because TBI patients often have other medical issues, individual screening is essential.
Understanding fever after an infusion
Because temporary fever is the most consistently reported side effect of intravenous MSCs, it helps to know what to expect. A low-grade fever, sometimes with chills or body aches, can appear within hours of the infusion and usually resolves within one to two days. It is thought to reflect a short-lived immune response to the cells rather than an infection. The nursing team monitors your temperature during observation, and paracetamol (acetaminophen) is generally used if needed, since anti-inflammatory drugs are avoided around treatment. For people with TBI, fever can sometimes worsen headache or fatigue temporarily, which is one reason observation after the infusion is valuable. A high, persistent or worsening fever is not expected and should always be reported.
Safety by route of administration
- Intravenous infusion: the most common route in our neurological protocols. It does not require brain surgery. Many cells are temporarily filtered by the lungs. Common effects are mild fever, headache and fatigue.
- Intrathecal (into the spinal fluid): studied in some neurological conditions. It can cause headache, back pain and, rarely, infection.
- Intra-arterial: brings cells closer to the brain but carries a risk of small vessel blockage.
- Direct surgical implantation: used in trials such as STEMTRA, with neurosurgical risks including bleeding, infection and seizures.
The route used for you, and its specific risks, should be clearly explained before treatment.
TBI-specific factors that affect safety
People living with TBI may have conditions that require special attention:
Seizures
Post-traumatic epilepsy is common after moderate to severe TBI. Seizures should be well controlled before treatment, and anti-seizure medications should be continued on schedule.
Shunts and prior surgery
Some patients have a ventriculoperitoneal shunt for hydrocephalus or have had a craniectomy or cranioplasty. These do not automatically exclude treatment but must be reviewed.
Blood thinners
Anticoagulants and antiplatelet drugs affect bleeding risk for any injection. They should never be stopped without medical guidance.
Swallowing, mobility and communication
Dysphagia, limited mobility or communication difficulties require planning for meals, transfers and monitoring during the stay.
Mood and cognition
Fatigue, sensitivity to noise or light, and anxiety can make travel more stressful. A calm, well-planned itinerary helps. Family members or caregivers are encouraged to share observations about behavior, sleep and energy, because they often notice changes before the patient does, both before and after treatment.
Other conditions
Heart disease, uncontrolled blood pressure, diabetes, active infections and a history of cancer within the past five years are evaluated or may exclude treatment.
Long-term safety
Most clinical trials follow patients for months to a few years. Within that time frame, analyses have not shown increased rates of cancer, abnormal tissue formation or serious infections with MSCs. This is reassuring, partly because MSCs generally do not persist in the body for long and act through temporary signals. However, rare events can only be fully excluded with larger numbers of patients and longer follow-up, which is why researchers and regulators continue to recommend long-term monitoring. In practical terms, this means you should keep your follow-up appointments, report any unexpected symptoms and share your treatment records with your regular physicians.
How we reduce risk
- Medical review before acceptance: records, imaging and medications are reviewed by a specialist. We decline treatment when we believe risks outweigh potential benefits or when expectations cannot be met.
- Pre-treatment testing: blood tests on arrival, including a complete blood count, metabolic panel, urinalysis and tumor markers.
- Quality-controlled cells: donor screening, infectious disease testing, and laboratory quality testing before release.
- Appropriate dosing and infusion speed, with monitoring of vital signs.
- Overnight observation with nursing supervision after treatment when indicated.
- Clear post-treatment instructions and follow-up calls.
Safety and results
A safe treatment can still produce different results in different patients. Functional improvement after TBI varies between patients. A safe treatment is one where the risks are known, minimized and reasonable compared with the potential benefit for your specific situation.
Regulatory context
The FDA has not approved stem cell products for TBI and warns patients about unapproved products sold without proper oversight. In Japan, a specific surgically implanted cell product received conditional, time-limited approval in 2024 for chronic motor deficits after TBI. In Mexico, establishments that handle stem cells operate under sanitary licenses from COFEPRIS. Ask any provider for documentation of the cells and the facility.
Who may be a safe candidate
- Medically stable, with controlled seizures if present.
- No recent neurosurgery planned or pending.
- Blood thinners reviewed and managed.
- No active infection and no cancer history within the past five years.
- Clear goals and access to ongoing rehabilitation.
- A caregiver or companion available during travel when cognitive or mobility limitations make independent travel difficult.
The National Institute of Neurological Disorders and Stroke (NINDS) emphasizes that rehabilitation remains central to TBI recovery; any regenerative treatment should support, not replace, that work.
Signs to report after treatment
Contact the medical team or seek urgent care if you experience a seizure, severe or worsening headache, high or persistent fever, new weakness, confusion, shortness of breath, chest pain or signs of infection at any injection site.
What our patients usually receive
Based on the treatment plans our team prepares for patients, a typical protocol at Stem Cell Mexico includes:
- Wharton's jelly MSCs by IV infusion, usually between 100 and 200 million cells, depending on the condition, body weight and medical review.
- An additional intrathecal application (similar to an epidural, usually about 60 million cells) for some neurological conditions, only after the doctor reviews your medical reports and confirms you are a candidate.
- One night at our facilities, sometimes two, with nursing and medical monitoring.
- Consultation with your doctor and the stem cell specialist, pre-treatment laboratory tests and ground transportation from the San Diego airport area.
- Complementary therapies, such as PRP, exosomes or NAD+, only when the doctor considers them useful; they are always listed in your written plan.
Recovery is gradual, and each person responds differently. Some patients begin noticing changes within the first weeks, while others notice them over the following months, which is why our team stays in contact after treatment to follow your progress and decide whether a second application could help.
Questions to ask during your evaluation
- What route and dose do you recommend, and what are their specific risks?
- How do my seizures, shunt or medications affect safety?
- What monitoring will I have during and after treatment?
- What documentation will I receive about the cells?
- In what situations would you advise against treatment?
Bottom line
MSC therapy for traumatic brain injury has a generally favorable safety record in clinical research, especially with IV administration, with temporary fever as the most common side effect. Safety depends on careful screening of TBI-related factors, quality-controlled cells and proper monitoring. A medical evaluation can help determine whether this type of regenerative treatment is appropriate and safe for your injury, goals and medical history.
References
- National Institute of Neurological Disorders and Stroke (NINDS, NIH): Traumatic brain injury (opens in a new tab)
- Kawabori M et al. Mesenchymal stromal cell implants for chronic motor deficits after traumatic brain injury (STEMTRA trial). Neurology, 2024 (opens in a new tab)
- Thompson M et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis. EClinicalMedicine, 2020 (opens in a new tab)
- Hum C et al. Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis. Stem Cells Translational Medicine, 2026 (opens in a new tab)
